All the news Showing 10 of 676 articles from: TherapiesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources New triple DAA combo cures 96-99% of people with all genotypes of hepatitis C Liz Highleyman / 08 November 2016 A new three-drug regimen of sofosbuvir, velpatasvir and voxilaprevir, taken without ribavirin for 8 weeks, produced sustained virological response in 96% of previously untreated people with all hepatitis C virus (HCV) genotypes, while ... Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir Gilead press release / 27 October 2016 Sofosbuvir/velpatasvir in chronic hepatitis C: hint of added benefit in two of ten subindications IQWIG / 17 October 2016 AbbVie 3D regimen taken for 8 weeks cures almost all HCV genotype 1b patients without cirrhosis Liz Highleyman / 06 October 2016 AbbVie’s paritaprevir-based ‘3D’ regimen taken for just 8 weeks without ribavirin led to sustained virological response in 98% of easier-to-treat patients with hepatitis C virus (HCV) genotype 1b who did not have cirrhosis, ... 100% cure rate for people with HCV genotype 1 treated with AL-335, odalasvir and simeprevir for 6 or 8 weeks Liz Highleyman / 05 October 2016 A triple regimen containing two experimental hepatitis C drugs – AL-335 and odalasvir – plus simeprevir taken for either 6 or 8 weeks cured all participants with previously untreated genotype 1 hepatitis ... Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV Achillion press release / 26 September 2016 NICE says yes to another hepatitis C drug NICE / 26 September 2016 Exviera, Viekirax regimen shows high SVR in HCV genotype 1b after 8 weeks Healio / 26 September 2016 Hepatitis C vaccine development shows progress but scientific barriers remain Liz Highleyman / 12 September 2016 An effective vaccine may be necessary to eliminate hepatitis C virus (HCV) but development has been hampered by several challenges including the variability of the virus and incomplete natural immunity, according to presentations ... Achillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV Achillion press release / 09 September 2016 ← Prev1...56789...68Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds